Search Results for “aging” – Page 18 – media

P-MEC Asia

Organiser：Informa Markets Time：July 16th – 18th, 2025 address：Kompleks MITEC @ KL Metropolis, 8, Jalan Dutamas 2, Segambut, 50480 Kuala Lumpur, Federal Territory of Kuala Lumpur, Malaysia Exhibition hall：Malaysia International Trade and Exhibition Centre (MITEC) Product range: Pharmaceutical Raw Material Equipment: Reactors, Drying Equipment, Crystallization Equipment, Centrifuges, Extraction Equipment, Heat Exchangers, Storage Equipment, Filtration Equipment, Evaporation Equipment, Distillation Equipment, Screening Machinery, Filter Presses, Homogenizers, etc. Pharmaceutical Preparation Equipment: Pill Machinery, Ointment Machinery, Eye Drop Machinery, Tablet Machinery, Tincture & Syrup Machinery, Instant Granule Machinery, Soft Capsule Machinery, Aqueous Injection Machinery, Hard Capsule Machinery, Suppository Machinery, Oral Liquid Machinery, Pharmaceutical Film Machinery, Aerosol Machinery, Powder & Aqueous Injection Machinery, Infusion Machinery, Tablet Presses, Coating Machines, Pharmaceutical Filling Machines, Jet Mills, Pharmaceutical Grinders, Low-Temperature Grinders, Pharmaceutical Grinding Units, Mechanical Pharmaceutical Grinders, Ultra-fine Grinders, Granulators, Mixing Equipment, Bottle Conveyors, Bottle Sorting Machines, Bottle Washers, Aeration Devices, Oscillating Cappers, Feeding Devices, etc. Pharmaceutical Packaging Machinery: ...
- Source: drugdu
- 204
- September 17, 2024
After CXO, will the United States start to take action against Chinese APIs?

In response to whether the bill is feasible, the FDA once said, “If there is not enough data to calculate which APIs come from China, what proportion and how much impact, no one can guarantee that there will not be fatal drug shortages, and no one is willing to take such responsibility.” Now, the API industry base survey and assessment initiated by the U.S. Department of Commerce is a comprehensive survey of industry data, which means possible variables in the future. According to reports, in July this year, the Bureau of Industry and Security (BIS) of the U.S. Department of Commerce officially announced that it would cooperate with the Strategic Preparedness and Response Administration (ASPR) under the U.S. Department of Health and Human Services (HHS) to conduct a comprehensive investigation and assessment of the U.S. active pharmaceutical ingredients, or API industry base. The survey aims to understand the supply chain ...
- Source: drugdu
- 53
- September 16, 2024
Traditional Chinese Medicine Brands Accelerate Penetration into Young Consumer Groups

In recent years, health-oriented and personalized dietary trends, exemplified by new-style tea beverages, have rapidly gained popularity among young consumers. Building on this foundation, with an increasing awareness of health and wellness, traditional Chinese medicine (TCM) health drinks, with their unique health philosophies and rich cultural backgrounds, have gradually won recognition among younger demographics. Reports from the China Securities Journal indicate that it’s not just beverage products; under consumer demand, renowned TCM brands such as Tong Han Chun Tang, Tong Ren Tang, Lei Yun Shang, and Hu Qing Yu Tang are actively launching new products featuring TCM ingredients, including medicinal dishes, herbal scents, and skincare items, tailored to meet the genuine needs of younger consumers. Experts believe that as these brands expand their product lines and target consumption scenarios, it will help rejuvenate the long-standing TCM brands. Targeting Youth to Enhance Product Offerings Historically, traditional TCM shops have not been ...
- Source: drugdu
- 101
- September 13, 2024
Focusing on the Frontiers of Biomedicine and Creating an Open Source Innovation Ecosystem.

Recently, a reporter from China Securities Journal visited the Shanghai Frontier Biomedical Innovation Center. Driving into the core area of the Zhangjiang Science City, a national-level biomedical base, one can see a modern, curved building from afar. Approaching closer, the open interior, visible through the yellow and white glass, creates a sense of freedom and positivity. “Currently, 10 resident companies and 11 ecological partners have signed cooperation agreements with Shanghai Frontier,” a representative from Shanghai Frontier stated. The center aims to create a “wall-less R&D center,” breaking down traditional barriers and promoting interaction and collaboration among experts, scholars, businesses, and investors from various fields and backgrounds, including industry, education, research, healthcare, and finance. Looking ahead, Shanghai Frontier will focus on cutting-edge biotechnologies such as gene and cell therapy, nucleic acid drugs, and conjugated drugs, hoping to discover and nurture highly innovative and competitive companies and projects while encouraging high-potential innovations ...
- Source: drugdu
- 112
- September 13, 2024
Ultrasonic Knife Alliance’s centralized procurement is imminent, how can China’s brands “overtake on the bend”

On September 3, 2024, the Shenzhen Public Resource Trading Center once again publicly solicited opinions on the “Continuation of Procurement Documents for Centralized Volume Purchase Agreement of Ultrasonic Knife Heads and Pre filled Catheter Flushers (Draft for Comments)”. Enterprises can provide feedback before 17:00 on September 10. The variety of this procurement is ultrasonic blade head (disposable/reusable/integrated handle ultrasonic blade head). After two years, this market is once again experiencing a tense moment. The Guangdong Alliance’s centralized procurement of ultrasonic knives will be launched, and market competition has entered a white hot stage Since the first centralized procurement of ultrasonic cutting heads in Fujian Province in 2020, as of 2024, the centralized procurement areas for ultrasonic cutting heads have spread throughout the country. After this launch, the Guangdong Alliance will become the largest alliance for centralized procurement of ultrasonic knives. At the end of 2021, Guangdong led a 16 province ...
- Source: drugdu
- 83
- September 13, 2024
Ten measures are favorable for innovative medical devices

Recently, the Guangzhou Municipal Health Commission of Guangdong Province issued the “Ten Measures of the Guangzhou Municipal Health Commission to Support the High-quality Development of Innovative Drugs and Devices”, covering the entire process of product research and development-hospital use-payment expansion. The notice proposes to urge medical institutions to hold at least one working meeting of the medical device-related committee every quarter, and hold a meeting within one month after the publication of the “Guangzhou Innovative Drug and Device Product Catalog”, and promptly include innovative drugs and devices in the medical institution’s drug or device catalog as needed, so as to achieve “all-out allocation” and give priority to selection. Encourage qualified medical institutions to accelerate the application of innovative medical devices such as active surgical instruments, passive implantable devices, medical software, medical imaging, radiotherapy, surgical robots, etc., and orderly promote the iterative upgrade of medical institutions’ equipment and facilities. ...
- Source: https://mp.weixin.qq.com/
- 51
- September 12, 2024
Orthopedic giant, head coach of Greater China region resigns

Recently, global orthopedic giant Xerox announced that Mr. Hu Hai, Managing Director of Xerox Greater China, has decided to leave Xerox on September 26th to seek external development opportunities. At present, Hu Hai has not announced where his next destination will be, and Shi Lehui has not yet announced a new successor. Retired veteran resigns In September 2021, Xerox announced the departure of its Managing Director for Greater China, Alaeddin Ahram, and the new Managing Director for Greater China, Hu Hai, took office on September 27th. Hu Hai is a veteran in the field of medical devices, with over 30 years of experience in the field, especially in orthopedics. Prior to joining Xerox, he had extensive work experience in several giant companies, including serving as Vice President of the Joint Division in China at Johnson&Johnson Medical, Vice President of Depuy Synthes in China at Johnson&Johnson Orthopedics, the first CEO and ...
- Source: drugdu
- 53
- September 12, 2024
Optical equipment giant, entering the ‘ophthalmic metaverse’

Recently, optical giant Zeiss announced that it has reached a cooperation agreement with Swiss AR/VR company Creal to jointly develop a new digital vision healthcare platform based on light field display technology, planning to completely revolutionize existing vision diagnosis and treatment procedures. Light field display is a method that utilizes ray tracing to reconstruct 3D scenes in space, and is currently the most likely practical 3D display technology. Compared with holographic display technology, which is also a true 3D display technology, light field display has smaller data volume, lower cost, and smaller volume. Zeiss will introduce CREAL’s light field display technology to create a device that can digitally reproduce real refractive testing. The new device will be able to virtually simulate traditional glasses and contact lenses, eliminating the need to switch lenses repeatedly. Objects in front of us will be displayed at different focal lengths, and through precise digital imaging, ...
- Source: drugdu
- 50
- September 12, 2024
Lianying ranks first in domestic production

Recently, the US FDA updated the list of authorized artificial intelligence and machine learning (AI/ML) medical devices. This list is a barometer of the health status of the artificial intelligence industry, and updates show that the FDA is maintaining a rapid pace of authorization. In the past few years, the FDA’s AI authorization has maintained double-digit growth, which reflects the increasing number of submissions received by the FDA from AI developers. AI/ML medical equipment explosion In the past, the FDA usually updated the list of approved AI/ML devices once a year, but with the frequent changes and approvals of artificial intelligence technology, the FDA has increased the frequency of updating the list. This list update includes 61 new approvals, including products approved between March 31st and June 25th. Similar to previous updates, applications targeting radiology accounted for the majority of the new licenses, with 44 products on the list since ...
- Source: drugdu
- 73
- September 11, 2024
635 million US dollars! Anmai Biological BCMA × CD3 Double Antibody Successfully Goes to Sea

Anmai Biotechnology announced that it has reached a licensing agreement with Vignette Bio for the T cell conjugation (TCE) molecule EMB-06 targeting BCMA. According to the agreement, Amway Bio will grant Vignette the exclusive right to develop and commercialize EMB-06 outside the Greater China region (including Chinese Mainland, Hong Kong, Macao and Taiwan), and Amway Bio will reserve the right of EMB-06 in the Greater China region. Anmai Biotechnology will receive a total down payment of $60 million in cash and Vignette equity, and will have the right to receive up to $575 million in milestone payments for development, listing, and commercialization, as well as revenue sharing based on net sales. EMB-06 is the first TCE molecule developed under the T cell conjugation platform of Anmai Biotechnology, which combines Anmai Biotechnology’s self-developed FIT Ig bispecific antibody platform and CD3 binding domain library, as well as Anmai Biotechnology’s internal new drug ...
- Source: drugdu
- 68
- September 11, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.